Pharmacyclics Announces Presentations on Its Novel BTK and HDACInhibitors at the American Society of Hematology 49th AnnualMeeting
SUNNYVALE, Calif., November 29, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced multiple presentations and published abstracts regarding its novel Bruton's tyrosine kinase (BTK) inhibitor and histone deacetylase (HDAC) inhibitor compounds. The presentations will take place at the American Society of Hematology (ASH) 49th Annual Meeting, in Atlanta, GA, December 8-11, 2007.
The presentations and published abstracts are as follows: Saturday, December 8, 2007 Session: Lymphoma: Pre-Clinical: Chemotherapy and Biologic Agents I Poster Presentation: Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma Abstract #1377: 5:30 p.m. - 7:30 p.m. ET Location: Hall B4 Presenter: Sriram Balasubramanian, Ph.D.; Pharmacyclics, Inc. Session: Molecular Pharmacology: Novel Therapies Poster Presentation: Targeting Btk in Lymphoma: PCI-32765 Inhibits Tumor Growth in Mouse Lymphoma Models and a Fluorescent Analog of PCI-32765 is an Active-Site Probe that Enables Assessment of Btk Inhibition in vivo Abstract #1592: 5:30 p.m. - 7:30 p.m. ET Location: Hall B4 Presenter: Lee Honigberg, Ph.D.; Pharmacyclics, Inc. Session: Chronic Myeloid Leukemia: Biology and Pathophysiology I Poster Presentation: Bruton's Tyrosine Kinase (BTK) is not Required for . BCR-ABL-Mediated Transformation of Hematopoietic Cells Abstract #1015: 5:30 p.m. - 7:30 p.m. ET Location: Hall B4 Presenter: Mary MacPartlin, Ph.D.; Oregon Health & Science University Cancer Institute Monday, December 10, 2007 Session: Non-Hodgkin's Lymphoma: Biology-T-Cell and B-Cell Poster Presentation: Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB Mediated Pathways Abstract #3589: 5:00 p.m. - 7:00 p.m. ET Location: Hall B4 Presenter: Savita Bhalla, Ph.D.; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center
All abstracts will appear in the November 16, 2007 issue of Blood, The Journal of The American Society of Hematology.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with whole brain radiation therapy for treatment of brain metastases from non-small cell lung cancer was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc.
Web site: http://www.pharmacyclics.com/
Ticker Symbol: (NASDAQ-NMS:PCYC)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2007